Teduglutide

World Peptide Foundation

WORLD PEPTIDEFOUNDATION

The Human Peptide Project™

Contribute an Observation

WPF flagship programsThe Human Peptide Project™The Living Peptide Record™

English

Loading public peptide profiles…Open the Master Registry

Teduglutide — Peptide Scientific Intelligence

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

6 conclusions connected to 0 featured studies

Teduglutide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.

Inspect the reconciled evidence atlas

Evidence boundary

Featured evidence

Domain links

See graph

Contradicting

With explicit limits

What this does not establish

• WPF’s atlas includes pediatric case reports, observational cohorts of adults, and monitoring guidance for people receiving teduglutide. These sources can inform questions about long-term care, but a case report or observational association cannot alone establish the size of a causal treatment effect.
• This Directory entry has no published source-linked citations or jurisdiction-specific regulatory records. Adults and children, differing underlying anatomy, parenteral-support outcomes, and safety monitoring must be assessed separately against primary and official sources.
• The presence of published evidence does not by itself establish safety, efficacy, causation or clinical benefit.

Inspect the published evidence record176 governed records · titles, provenance, and original-source linksOpen records ↓

2023Phase 3 human evidence

Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.

Content-verified record concerning Teduglutide: "Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension." Abstract excerpt: The short- and long-term efficacy, safety, and pharmacokinetics of teduglutide were analyzed in adult Japanese patients with short bowel syndrome and intestinal failure (SBS-IF). Patients received teduglutide 0.05 mg/kg/day in clinical trials (TED-C14-004, SHP633-306, and extension SHP633-307). Data were analyzed at 24 weeks and an interim data cut-off of 4.5 years. The parenteral s

Source: peer_reviewed_research
DOI: 10.1007/s00595-022-02587-4
PubMed: 36201060

Open original source

2020Phase 3 human evidence

Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓

Chemical identity

Molecular and structural record

Structured record

Molecular formula: C164H252N44O55S
Molecular weight: 3752.1
SMILES: CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N
InChI: InChI=1S/C164H252N44O55S/c1-21-77(11)126(156(255)187-95(44-46-114(167)214)141(240)206-130(83(17)211)160(259)186-93(42-33-34-49-165)140(239)202-129(80(14)24-4)159(258)208-131(84(18)212)161(260)200-111(163(262)263)66-125(230)231)203-151(250)100(54-76(9)10)189-145(244)103(57-88-67-175-92-41-32-31-40-90(88)92)192-147(246)105(60-116(169)216)199-157(256)127(78(12)22-2)204-152(251)102(56-87-38-29-26-30-39-87)190-149(248)109(64-123(226)227)195-137(236)94(43-35-50-174-164(171)172)183-134(233)82(16)179-133(232)81(15)180-142(241)98(52-74(5)6)188-146(245)104(59-115(168)215)194-150(249)110(65-124(228)229)196-143(242)99(53-75(7)8)198-158(257)128(79(13)23-3)205-162(261)132(85(19)213)207-153(252)106(61-117(170)217)193-139(238)97(48-51-264-20)185-138(237)96(45-47-120(220)221)184-148(247)108(63-122(224)225)197-155(254)113(72-210)201-144(243)101(55-86-36-27-25-28-37-86)191-154(253)112(71-209)182-119(219)70-177-136(235)107(62-121(222)223)181-118(218)69-176-135(234)91(166)58-89-68-173-73-178-89/h25-32,36-41,67-68,73-85,91,93-113,126-132,175,209-213H,21-24,33-35,42-66,69-72,165-166H2,1-20H3,(H2,167,214)(H2,168,215)(H2,169,216)(H2,170,217)(H,173,178)(H,176,234)(H,177,235)(H,179,232)(H,180,241)(H,181,218)(H,182,219)(H,183,233)(H,184,247)(H,185,237)(H,186,259)(H,187,255)(H,188,245)(H,189,244)(H,190,248)(H,191,253)(H,192,246)(H,193,238)(H,194,249)(H,195,236)(H,196,242)(H,197,254)(H,198,257)(H,199,256)(H,200,260)(H,201,243)(H,202,239)(H,203,250)(H,204,251)(H,205,261)(H,206,240)(H,207,252)(H,208,258)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,262,263)(H4,171,172,174)/t77-,78-,79-,80-,81-,82-,83+,84+,85+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,126-,127-,128-,129-,130-,131-,132-/m0/s1
InChIKey: CILIXQOJUNDIDU-ASQIGDHWSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

2004 · study · Temporal status not established
Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.
peer_reviewed_research
2005 · study · Temporal status not established
Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
peer_reviewed_research
2006 · study · Temporal status not established
Teduglutide for the treatment of short bowel syndrome.
peer_reviewed_research
2006 · study · Temporal status not established
Teduglutide
other
2008 · study · Temporal status not established
Teduglutide in intestinal adaptation and repair: light at the end of the tunnel.
peer_reviewed_research
2008 · study · Temporal status not established
Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects.
peer_reviewed_research
2009 · study · Temporal status not established
Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome.
peer_reviewed_research
2010 · study · Temporal status not established
Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease.
peer_reviewed_research
2010 · study · Temporal status not established
Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.
peer_reviewed_research
2010 · study · Temporal status not established
Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.
peer_reviewed_research
2011 · study · Temporal status not established
Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
peer_reviewed_research
2011 · study · Temporal status not established
Effect of different doses of GLP-2 (Teduglutide) on acute esophageal lesion due to acid-pepsin perfusion in male rats.
peer_reviewed_research
2011 · study · Temporal status not established
Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome.
peer_reviewed_research
2012 · study · Temporal status not established
Teduglutide, a glucagon-like peptide 2 analogue: a novel protective agent with anti-apoptotic and anti-oxidant properties in mice with lung injury.
peer_reviewed_research
2012 · study · Temporal status not established
Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
peer_reviewed_research
2012 · study · Temporal status not established
A Thorough QT Study of Teduglutide in Healthy Subjects.
peer_reviewed_research
2012 · study · Temporal status not established
Teduglutide and short bowel syndrome: every night without parenteral fluids is a good night.
peer_reviewed_research
2012 · study · Temporal status not established
Treatment of adult short bowel syndrome patients with teduglutide.
peer_reviewed_research
2013 · study · Temporal status not established
Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
peer_reviewed_research
2013 · study · Temporal status not established
Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells.
peer_reviewed_research
2013 · study · Temporal status not established
Teduglutide for the treatment of short bowel syndrome.
peer_reviewed_research
2013 · study · Temporal status not established
Teduglutide: a review of its use in the treatment of patients with short bowel syndrome.
peer_reviewed_research
2013 · study · Temporal status not established
Pharmacokinetics of teduglutide in subjects with renal impairment.
peer_reviewed_research
2013 · study · Temporal status not established
Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.
peer_reviewed_research
2013 · study · Temporal status not established
Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.
peer_reviewed_research
2013 · study · Temporal status not established
Teduglutide injection (Gattex) for short bowel syndrome.
peer_reviewed_research
2013 · study · Temporal status not established
Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects.
peer_reviewed_research
2013 · study · Temporal status not established
[Short bowel syndrome. GLP-2 analog teduglutide].
peer_reviewed_research
2013 · study · Temporal status not established
The long road to a new short-bowel therapy: teduglutide for clinical use.
peer_reviewed_research
2013 · study · Temporal status not established
Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure.
peer_reviewed_research
2014 · study · Temporal status not established
A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.
peer_reviewed_research
2014 · study · Temporal status not established
Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.
peer_reviewed_research
2014 · study · Temporal status not established
Teduglutide for the Treatment of Short Bowel Syndrome.
peer_reviewed_research
2014 · study · Temporal status not established
Vortioxetine hydrobromide, crofelemer, and teduglutide.
peer_reviewed_research
2014 · study · Temporal status not established
Utility of a population pharmacokinetic meta analysis during the approval process of teduglutide for the treatment of short bowel syndrome.
systematic_review_or_meta_analysis
2015 · study · Temporal status not established
Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials.
peer_reviewed_research
2015 · study · Temporal status not established
[Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for teduglutide-benefit assessment according to § 35a SGB V the G-BA].
peer_reviewed_research
2015 · study · Temporal status not established
Teduglutide: a guide to its use in short bowel syndrome.
peer_reviewed_research
2016 · study · Temporal status not established
Response to "Teduglutide and Intestinal Permeability in Short Bowel Syndrome".
peer_reviewed_research
2016 · study · Temporal status not established
Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.
systematic_review_or_meta_analysis
2016 · study · Temporal status not established
Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome.
peer_reviewed_research
2016 · study · Temporal status not established
Teduglutide and Intestinal Permeability in Short Bowel Syndrome.
peer_reviewed_research
2016 · study · Temporal status not established
Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.
peer_reviewed_research
2016 · study · Temporal status not established
Clinical Management of Patients With Parenteral Nutrition-Dependent Short Bowel Syndrome During Teduglutide Therapy.
peer_reviewed_research
2016 · study · Temporal status not established
A Patient With Parenteral Nutrition-Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide.
peer_reviewed_research
2017 · study · Temporal status not established
Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide.
peer_reviewed_research
2017 · study · Temporal status not established
Enteral Autonomy with Teduglutide Treatment of Intestinal Failure/Short Bowel Syndrome with Depleted Central Venous Access.
peer_reviewed_research
2017 · study · Temporal status not established
Results of 12-month rescue treatment with Teduglutide in severely active and parenteral nutrition-dependent Crohn's disease.
peer_reviewed_research
2017 · study · Temporal status not established
Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.
peer_reviewed_research
2017 · study · Temporal status not established
Teduglutide effects on gene regulation of fibrogenesis on an animal model of intestinal anastomosis.
peer_reviewed_research
2017 · study · Temporal status not established
The Polish Intestinal Failure Centres' consensus on the use of teduglutide for the treatment of short bowel syndrome.
peer_reviewed_research
2017 · study · Temporal status not established
Intestinal inflammatory and redox responses to the perioperative administration of teduglutide in rats.
peer_reviewed_research
2017 · study · Temporal status not established
Teduglutide for treatment of adult patients with short bowel syndrome.
peer_reviewed_research
2017 · study · Temporal status not established
Teduglutide: A Review in Short Bowel Syndrome.
peer_reviewed_research
2017 · study · Temporal status not established
Teduglutide-Stimulated Intestinal Adaptation Is Complemented and Synergistically Enhanced by Partial Enteral Nutrition in a Neonatal Piglet Model of Short Bowel Syndrome.
peer_reviewed_research
2017 · study · Temporal status not established
Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.
peer_reviewed_research
2017 · study · Temporal status not established
Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.
peer_reviewed_research
2018 · study · Temporal status not established
Further improvement after 24-month treatment with teduglutide in a patient with active Crohn's disease and short bowel syndrome.
peer_reviewed_research
2018 · study · Temporal status not established
Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series.
peer_reviewed_research
2018 · study · Temporal status not established
De Novo Development of Hamartomatous Duodenal Polyps in a Patient With Short Bowel Syndrome During Teduglutide Therapy: A Case Report.
peer_reviewed_research
2018 · study · Temporal status not established
Tissular growth factors profile after teduglutide administration on an animal model of intestinal anastomosis.
peer_reviewed_research
2018 · study · Temporal status not established
Intestinal Epithelial Stem Cells: Distinct Behavior After Surgical Injury and Teduglutide Administration.
peer_reviewed_research
2018 · study · Temporal status not established
Teduglutide-induced stem cell function in intestinal repair.
peer_reviewed_research
2018 · study · Temporal status not established
Teduglutide for the treatment of short bowel syndrome - a safety evaluation.
peer_reviewed_research
2018 · study · Temporal status not established
GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting.
peer_reviewed_research
2018 · study · Temporal status not established
Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
peer_reviewed_research
2018 · study · Temporal status not established
Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome.
peer_reviewed_research
2018 · study · Temporal status not established
Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study.
peer_reviewed_research
2019 · study · Temporal status not established
Off-Label Teduglutide Therapy in Non-intestinal Failure Patients with Chronic Malabsorption.
peer_reviewed_research
2019 · study · Temporal status not established
Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature.
peer_reviewed_research
2019 · study · Temporal status not established
Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome.
peer_reviewed_research
2019 · study · Temporal status not established
Effect of teduglutide on restoring oral autonomy for magnesium in two patients with short bowel.
peer_reviewed_research
2019 · study · Temporal status not established
Experience with teduglutide treatment for short bowel syndrome in clinical practice.
peer_reviewed_research
2020 · study · Temporal status not established
Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.
peer_reviewed_research
2020 · study · Temporal status not established
Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study.
peer_reviewed_research
2020 · study · Temporal status not established
Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.
peer_reviewed_research
2020 · study · Temporal status not established
Small-Bowel Adaptation: A Case of Morphological Changes Induced by Teduglutide in Short-Bowel Syndrome With Intestinal Failure.
peer_reviewed_research
2020 · study · Temporal status not established
Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series.
peer_reviewed_research
2020 · study · Temporal status not established
Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report.
peer_reviewed_research
2020 · study · Temporal status not established
GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives.
peer_reviewed_research
2020 · study · Temporal status not established
Translation of Evidence Into Practice With Teduglutide in the Management of Adults With Intestinal Failure due to Short-Bowel Syndrome: A Review of Recent Literature.
peer_reviewed_research
2020 · study · Temporal status not established
Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.
peer_reviewed_research
2020 · study · Temporal status not established
The Glucagon-Like Peptide 2 Analog Teduglutide Reversibly Associates to Form Pentamers.
peer_reviewed_research
2020 · study · Temporal status not established
Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency.
peer_reviewed_research
2020 · study · Temporal status not established
Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials.
peer_reviewed_research
2020 · study · Temporal status not established
Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.
peer_reviewed_research
2020 · study · Temporal status not established
Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data.
peer_reviewed_research
2020 · study · Temporal status not established
[Is there life after teduglutide?]
peer_reviewed_research
2020 · study · Temporal status not established
Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials.
peer_reviewed_research
2021 · study · Temporal status not established
Imaging as predictor of clinical response to teduglutide in adult patients with short bowel syndrome with chronic intestinal failure.
peer_reviewed_research
2021 · study · Temporal status not established
De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short-Bowel Syndrome: A Case Report.
peer_reviewed_research
2021 · study · Temporal status not established
Long-term Effects of Teduglutide on Intestinal Mucosa in a Patient With Crohn's Disease and Short Bowel Syndrome: Clinical, Endoscopic and Histological Data Compared.
peer_reviewed_research
2021 · study · Temporal status not established
Long-Term Outcomes With Teduglutide From a Single Center.
peer_reviewed_research
2021 · study · Temporal status not established
Intestinal iatrogenic hyperadaptation in patients with short bowel syndrome and Crohn's disease: Is this an indication for mandatory lifelong injections of teduglutide?
peer_reviewed_research
2021 · study · Temporal status not established
Teduglutide Therapy in 2 Patients With Short-Bowel Syndrome and Familial Adenomatous Polyposis.
peer_reviewed_research
2021 · study · Temporal status not established
Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.
peer_reviewed_research
2021 · study · Temporal status not established
Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome.
peer_reviewed_research
2021 · study · Temporal status not established
Expression, purification and molecular dynamics simulation of extracellular domain of glucagon-like peptide-2 receptor linked to teduglutide.
peer_reviewed_research
2021 · study · Temporal status not established
Teduglutide for pediatric short bowel syndrome patients.
systematic_review_or_meta_analysis
2021 · study · Temporal status not established
Designing Novel Teduglutide Analogues with Improved Binding Affinity: An In Silico Peptide Engineering Approach.
peer_reviewed_research
2021 · study · Temporal status not established
Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support.
peer_reviewed_research
2021 · study · Temporal status not established
Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies.
peer_reviewed_research
2022 · study · Temporal status not established
Teduglutide for the treatment of low-output enterocutaneous fistula - A pilot randomized controlled study.
peer_reviewed_research
2022 · study · Temporal status not established
Hernia enlargement and pancreatitis in a patient with short bowel syndrome treated with teduglutide.
peer_reviewed_research
2022 · study · Temporal status not established
Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide-9 Years of Follow-Up.
peer_reviewed_research
2022 · study · Temporal status not established
Characterization of American teduglutide consumers from 2015 to 2020: A large database study.
peer_reviewed_research
2022 · study · Temporal status not established
Long-term results of teduglutide treatment for chronic intestinal failure - Insights from a national, multi-centric patient home-care service program.
peer_reviewed_research
2022 · study · Temporal status not established
The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience.
peer_reviewed_research
2022 · study · Temporal status not established
Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers.
peer_reviewed_research
2022 · study · Temporal status not established
Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS.
peer_reviewed_research
2022 · study · Temporal status not established
Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).
peer_reviewed_research
2022 · study · Temporal status not established
Teduglutide in short bowel syndrome patients: A way back to normal life?
peer_reviewed_research
2022 · study · Temporal status not established
Use of Teduglutide in Children With Intestinal Failure: A Systematic Review.
systematic_review_or_meta_analysis
2022 · study · Temporal status not established
Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.
systematic_review_or_meta_analysis
2023 · study · Temporal status not established
Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.
peer_reviewed_research
2023 · study · Temporal status not established
Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure.
peer_reviewed_research
2023 · study · Temporal status not established
Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications.
peer_reviewed_research
2023 · study · Temporal status not established
Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring.
peer_reviewed_research
2023 · study · Temporal status not established
Nutritional management of a patient with chronic intestinal failure and hemodialysis receiving teduglutide: A case report.
peer_reviewed_research
2023 · study · Temporal status not established
Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy.
peer_reviewed_research
2023 · study · Temporal status not established
Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes.
peer_reviewed_research
2023 · study · Temporal status not established
[Review of real-life teduglutide experience].
peer_reviewed_research
2023 · study · Temporal status not established
Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome.
peer_reviewed_research
2023 · study · Temporal status not established
[Expert recommendations on the use of teduglutide in pediatric patients with short bowel syndrome].
peer_reviewed_research
2023 · study · Temporal status not established
Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure-A Nested Matched Pair Real-World Study.
peer_reviewed_research
2023 · study · Temporal status not established
Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing.
peer_reviewed_research
2023 · study · Temporal status not established
Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome.
peer_reviewed_research
2023 · study · Temporal status not established
Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure.
peer_reviewed_research
2023 · study · Temporal status not established
Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.
peer_reviewed_research
2023 · study · Temporal status not established
Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.
peer_reviewed_research
2023 · study · Temporal status not established
Teduglutide for the treatment of short bowel syndrome: a double-edged sword?
peer_reviewed_research
2023 · study · Temporal status not established
Adult patients with short bowel syndrome treated with teduglutide: A descriptive cohort study.
peer_reviewed_research
2023 · study · Temporal status not established
The indications and results of the use of teduglutide in patients with short bowel.
peer_reviewed_research
2024 · study · Temporal status not established
Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults.
peer_reviewed_research
2024 · study · Temporal status not established
Reversal of Intestinal Failure With Teduglutide in <i>PERCC1</i>-Associated Enteropathy: A Case Report.
peer_reviewed_research
2024 · study · Temporal status not established
Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report.
peer_reviewed_research
2024 · study · Temporal status not established
Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry.
peer_reviewed_research
2024 · study · Temporal status not established
Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study.
peer_reviewed_research
2024 · study · Temporal status not established
The Impact of Teduglutide on Real-Life Health Care Costs in Children with Short Bowel Syndrome.
peer_reviewed_research
2024 · study · Temporal status not established
Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective.
peer_reviewed_research
2024 · study · Temporal status not established
Cost-Effectiveness of Teduglutide for Pediatric Patients with Short Bowel Syndrome in Japan, Including Caregiver Burden.
peer_reviewed_research
2024 · study · Temporal status not established
Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease.
peer_reviewed_research
2024 · study · Temporal status not established
Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure.
peer_reviewed_research
2024 · study · Temporal status not established
Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.
peer_reviewed_research
2024 · study · Temporal status not established
Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals.
peer_reviewed_research
2024 · study · Temporal status not established
Use of teduglutide in adults with short bowel syndrome-associated intestinal failure.
peer_reviewed_research
2024 · study · Temporal status not established
Long-term outcomes and adverse effects of teduglutide in patients with short bowel syndrome: Highlighting hyperamylasemia and hyperlipasemia.
systematic_review_or_meta_analysis
2025 · study · Temporal status not established
Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study.
peer_reviewed_research
2025 · study · Temporal status not established
Reduction of Parenteral Nutrition in Children with Short Bowel Syndrome Treated with Teduglutide: Experience from the Czech Republic.
peer_reviewed_research
2025 · study · Temporal status not established
Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide.
peer_reviewed_research
2025 · study · Temporal status not established
Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome.
peer_reviewed_research
2025 · study · Temporal status not established
Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey.
peer_reviewed_research
2025 · study · Temporal status not established
Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey.
peer_reviewed_research
2025 · study · Temporal status not established
Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine.
peer_reviewed_research
2025 · study · Temporal status not established
Forty-eight months outcomes of teduglutide treatment in adult stable patients with short bowel syndrome and home parenteral nutrition dependence: A real-world Italian single-center observational cohort study.
peer_reviewed_research
2025 · study · Temporal status not established
Encapsulation of hydrophobically ion-paired teduglutide in nanoemulsions: Effect of anionic counterions.
peer_reviewed_research
2025 · study · Temporal status not established
Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries.
peer_reviewed_research
2025 · study · Temporal status not established
Safety of Teduglutide for Managing Patients with Short Bowel Syndrome: A Systematic Review and Meta-analysis.
systematic_review_or_meta_analysis
2025 · study · Temporal status not established
Impact of teduglutide on pediatric short bowel syndrome: A systematic review and trial sequential meta-analysis.
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients.
peer_reviewed_research
2026 · study · Temporal status not established
Teduglutide use in haemodialysis-dependent renal failure from secondary hyperoxaluria in short bowel syndrome and type 3 intestinal failure - A case report.
peer_reviewed_research
2026 · study · Temporal status not established
Growth trajectories of children with short bowel syndrome during the first year of teduglutide treatment.
peer_reviewed_research
2026 · study · Temporal status not established
Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure.
peer_reviewed_research
2026 · study · Temporal status not established
Successful treatment with teduglutide in short bowel syndrome with intestinal failure secondary to small-bowel volvulus: a case report and literature review.
peer_reviewed_research
2026 · study · Temporal status not established
Clinical outcomes of teduglutide therapy in children with short bowel syndrome-associated intestinal failure: A single-center experience.
peer_reviewed_research
2026 · study · Temporal status not established
Efficacy and safety of teduglutide in children with short bowel syndrome: a narrative review.
peer_reviewed_research
2026 · study · Temporal status not established
Development of a consensus parenteral solution weaning algorithm for children with short-bowel syndrome associated intestinal failure responding to teduglutide therapy.
peer_reviewed_research
2026 · study · Temporal status not established
Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study.
peer_reviewed_research
2026 · study · Temporal status not established
Optimizing teduglutide treatment regimens in children with short bowel syndrome.
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
Association between teduglutide treatment and long-term reductions in parenteral support: An observational cohort study of adults with short bowel syndrome.
peer_reviewed_research
2026 · study · Temporal status not established
[Use of teduglutide in short bowel syndrome in infants, children and adolescents: Position paper of the working group "Chronic intestinal failure" of the Society for Paediatric Gastroenterology and Nutrition (GPGE)].
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome.
peer_reviewed_research
2026 · study · Temporal status not established
Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance.
peer_reviewed_research
2026 · study · Temporal status not established
Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide.
peer_reviewed_research
2026 · study · Temporal status not established
Assessing the health-related quality of life and clinical effect in children with short bowel syndrome receiving teduglutide treatment.
peer_reviewed_research
2026 · regulatory · Temporal status not established
Regulatory review: approved
European Union — EMA
2026 · regulatory · Temporal status not established
Regulatory review: approved
United States — FDA
2027 · study · Temporal status not established
Development of Teduglutide purity certified reference material (GBW09342) through amino acid-based isotope dilution mass spectrometry and sulfur-based isotope dilution inductively coupled plasma mass spectrometry.
peer_reviewed_research

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Teduglutide research, ranked and separated by purpose

Teduglutide: what this atlas does and does not establish

Practice-defining evidence

Strong supporting evidence

Contextual evidence

Signal-generating evidence

Suggested citation

No community pattern is displayed yet

The state of the record

Evidence, claims, and boundaries

6 conclusions connected to 0 featured studies

Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.

Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.

Chemistry and represented biological context

Molecular and structural record

Continue through the research system

Research discovery

How the scientific record is developing

Research chronology

Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.

Teduglutide for the treatment of short bowel syndrome.

Teduglutide

Teduglutide in intestinal adaptation and repair: light at the end of the tunnel.

Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects.

Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome.

Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease.

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.

Effect of different doses of GLP-2 (Teduglutide) on acute esophageal lesion due to acid-pepsin perfusion in male rats.

Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome.

Teduglutide, a glucagon-like peptide 2 analogue: a novel protective agent with anti-apoptotic and anti-oxidant properties in mice with lung injury.

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.

A Thorough QT Study of Teduglutide in Healthy Subjects.

Teduglutide and short bowel syndrome: every night without parenteral fluids is a good night.

Treatment of adult short bowel syndrome patients with teduglutide.

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.

Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells.

Teduglutide for the treatment of short bowel syndrome.

Teduglutide: a review of its use in the treatment of patients with short bowel syndrome.

Pharmacokinetics of teduglutide in subjects with renal impairment.

Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.

Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.

Teduglutide injection (Gattex) for short bowel syndrome.

Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects.

[Short bowel syndrome. GLP-2 analog teduglutide].

The long road to a new short-bowel therapy: teduglutide for clinical use.

Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure.

A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.

Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.

Teduglutide for the Treatment of Short Bowel Syndrome.

Vortioxetine hydrobromide, crofelemer, and teduglutide.

Utility of a population pharmacokinetic meta analysis during the approval process of teduglutide for the treatment of short bowel syndrome.

Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials.

[Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for teduglutide-benefit assessment according to § 35a SGB V the G-BA].

Teduglutide: a guide to its use in short bowel syndrome.

Response to "Teduglutide and Intestinal Permeability in Short Bowel Syndrome".

Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.

Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome.

Teduglutide and Intestinal Permeability in Short Bowel Syndrome.

Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.

Clinical Management of Patients With Parenteral Nutrition-Dependent Short Bowel Syndrome During Teduglutide Therapy.

A Patient With Parenteral Nutrition-Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide.

Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide.

Enteral Autonomy with Teduglutide Treatment of Intestinal Failure/Short Bowel Syndrome with Depleted Central Venous Access.

Results of 12-month rescue treatment with Teduglutide in severely active and parenteral nutrition-dependent Crohn's disease.

Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.

Teduglutide effects on gene regulation of fibrogenesis on an animal model of intestinal anastomosis.

The Polish Intestinal Failure Centres' consensus on the use of teduglutide for the treatment of short bowel syndrome.

Intestinal inflammatory and redox responses to the perioperative administration of teduglutide in rats.

Teduglutide for treatment of adult patients with short bowel syndrome.

Teduglutide: A Review in Short Bowel Syndrome.

Teduglutide-Stimulated Intestinal Adaptation Is Complemented and Synergistically Enhanced by Partial Enteral Nutrition in a Neonatal Piglet Model of Short Bowel Syndrome.

Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.

Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.

Further improvement after 24-month treatment with teduglutide in a patient with active Crohn's disease and short bowel syndrome.

Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series.

De Novo Development of Hamartomatous Duodenal Polyps in a Patient With Short Bowel Syndrome During Teduglutide Therapy: A Case Report.